929 related articles for article (PubMed ID: 8823358)
1. Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic characteristics.
Nakano J; Raj BK; Asagami C; Lloyd KO
J Invest Dermatol; 1996 Oct; 107(4):543-8. PubMed ID: 8823358
[TBL] [Abstract][Full Text] [Related]
2. Biologic roles of gangliosides G(M3) and G(D3) in the attachment of human melanoma cells to extracellular matrix proteins.
Nakano J; Yasui H; Lloyd KO; Muto M
J Investig Dermatol Symp Proc; 1999 Sep; 4(2):173-6. PubMed ID: 10536995
[TBL] [Abstract][Full Text] [Related]
3. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.
Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ
Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody.
Dippold WG; Knuth A; Meyer zum Büschenfelde KH
Cancer Res; 1984 Feb; 44(2):806-10. PubMed ID: 6362854
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
Ohta S; Honda A; Tokutake Y; Yoshida H; Hanai N
Cancer Immunol Immunother; 1993; 36(4):260-6. PubMed ID: 8439988
[TBL] [Abstract][Full Text] [Related]
6. Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells.
Zou W; Borrelli S; Gilbert M; Liu T; Pon RA; Jennings HJ
J Biol Chem; 2004 Jun; 279(24):25390-9. PubMed ID: 15047693
[TBL] [Abstract][Full Text] [Related]
7. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.
Chapman PB; Lonberg M; Houghton AN
Cancer Res; 1990 Mar; 50(5):1503-9. PubMed ID: 2105840
[TBL] [Abstract][Full Text] [Related]
8. The antibody to GD3 ganglioside, R24, is rapidly endocytosed and recycled to the plasma membrane via the endocytic recycling compartment. Inhibitory effect of brefeldin A and monensin.
Iglesias-Bartolomé R; Crespo PM; Gomez GA; Daniotti JL
FEBS J; 2006 Apr; 273(8):1744-58. PubMed ID: 16623710
[TBL] [Abstract][Full Text] [Related]
9. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells.
Lloyd KO; Gordon CM; Thampoe IJ; DiBenedetto C
Cancer Res; 1992 Sep; 52(18):4948-53. PubMed ID: 1516051
[TBL] [Abstract][Full Text] [Related]
10. Mouse monoclonal antibodies with specificity for the melanoma-associated ganglioside disialyllactosylceramide (GD3) also react with the structural analogue disialylparagloboside.
Brodin T; Hellström I; Hellström KE; Karlsson KA; Sjögren HO; Strömberg N; Thurin J
Biochim Biophys Acta; 1985 Dec; 837(3):349-53. PubMed ID: 3840699
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis.
Kanazawa J; Ohta S; Shitara K; Fujita F; Fujita M; Hanai N; Akinaga S; Okabe M
Cancer Immunol Immunother; 2000 Jul; 49(4-5):253-8. PubMed ID: 10941908
[TBL] [Abstract][Full Text] [Related]
12. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.
Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ
Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480
[TBL] [Abstract][Full Text] [Related]
13. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody.
Pukel CS; Lloyd KO; Travassos LR; Dippold WG; Oettgen HF; Old LJ
J Exp Med; 1982 Apr; 155(4):1133-47. PubMed ID: 7061953
[TBL] [Abstract][Full Text] [Related]
14. Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody, Leo Mel 3.
Werkmeister JA; Triglia T; Mackay IR; Dowling JP; Varigos GA; Morstyn G; Burns GF
Cancer Res; 1987 Jan; 47(1):225-30. PubMed ID: 3791209
[TBL] [Abstract][Full Text] [Related]
15. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.
Chapman PB; Gillies SD; Houghton AN; Reilly RM
Cancer Immunol Immunother; 1994 Sep; 39(3):198-204. PubMed ID: 7522964
[TBL] [Abstract][Full Text] [Related]
16. Characterization of ganglioside expression in human melanoma cells: immunological and biochemical analysis.
Kawashima I; Ozawa H; Kotani M; Suzuki M; Kawano T; Gomibuchi M; Tai T
J Biochem; 1993 Aug; 114(2):186-93. PubMed ID: 8262898
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of immunotoxin by antibody to ganglioside GD3: a novel drug delivery route for tumor cells.
Torres Demichelis V; Vilcaes AA; Iglesias-Bartolomé R; Ruggiero FM; Daniotti JL
PLoS One; 2013; 8(1):e55304. PubMed ID: 23383146
[TBL] [Abstract][Full Text] [Related]
18. Resistance of human melanoma cells against the cytotoxic and complement-enhancing activities of doxorubicin.
Panneerselvam M; Bredehorst R; Vogel CW
Cancer Res; 1987 Sep; 47(17):4601-7. PubMed ID: 3621156
[TBL] [Abstract][Full Text] [Related]
19. GD3 expression by cultured human tumor cells of neuroectodermal origin.
He X; Wikstrand CJ; Fredman P; Månsson JE; Svennerholm L; Bigner DD
Acta Neuropathol; 1989; 79(3):317-25. PubMed ID: 2609939
[TBL] [Abstract][Full Text] [Related]
20. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
